Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cisplatin + tirapazamine + vinorelbine
- Development stage
- Phase 3
- Lead developer
- Cancer Research UK
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
This combination is used in the treatment of non-small cell lung cancer (NSCLC). **Cisplatin** is a platinum-based chemotherapy drug that works by cross-linking DNA, which interferes with cell division. **Tirapazamine** is a hypoxic cytotoxin that targets cells in low oxygen environments, such as those found in solid tumors. **Vinorelbine** is a vinca alkaloid that inhibits microtubule formation, disrupting cell division.
02
Targets
DNAMicrotubule
Beyond the preview
Go deeper on cisplatin + tirapazamine + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cisplatin + tirapazamine + vinorelbine.